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ABSTRACT
Introduction Inflammatory bowel diseases (IBD) are 
among the most common chronic illnesses diagnosed 
in childhood. Transition from paediatric to adult care is a 
crucial phase. The implementation of joint visits during the 
transition period in IBD is widely recommended, however, 
strong evidence supporting their benefit is still missing. 
In this trial, we aim to prove the superiority of joint 
visits compared with usual care in improving transition 
outcomes of adolescents with IBD.
Methods and analysis This is a randomised controlled 
two- arm multicentre trial. A minimum of 160 adolescents 
with IBD aged between 16.75 and 17 years will be 
recruited from Hungarian tertiary IBD centres. After 
randomisation, eligible subjects in the intervention arm 
attend a total of four joint visits with adult and paediatric 
gastroenterologist between the ages of 17 and 18. In 
the control arm, adolescents meet only the paediatric 
gastroenterologist, but there is a balanced consultation 
between the two gastroenterologist regarding the patient’s 
treatment plan. Patients in both groups receive the same 
training and education, the only determinative difference 
between the two arms is the presence of the adult 
gastroenterologist at the joint visits. Data will be collected 
at inclusion, at transfer and 12 months post- transfer. 
Primary outcome is the change in health- related quality of 
life measured with the IMPACT- III questionnaire at 1 year 
after transfer. Secondary outcomes include the number 
of patients not lost to follow- up, healthcare utilisation, 
disease activity, medication adherence, self- efficacy, 
transition readiness and patient’s satisfaction. To compare 
the results of the two patient groups, two- sample T- test 
and Mann- Whitney test will be applied.
Ethics and dissemination The Scientific and Research 
Ethics Committee of the Hungarian Medical Research 
Council approved this study (50457-2/2019/EKU). Findings 
will be disseminated at conferences and in medical 
journals.
Trial registration number NCT04290156.
INTRODUCTION
Due to the increasing number of children diag-
nosed with chronic diseases, there is a growing 
need for reliable, evidence- based guidelines 
dealing with transitional care.1 The currently 
available guidelines on providing transitional 
care in inflammatory bowel disease (IBD) 
recommend the implementation of joint 
visits.2 3 However, these recommendations are 
mainly based on clinical experiences, rather 
than strong scientific evidence. In order to 
be able to assure a healthcare service of the 
highest quality for adolescent patients with 
IBD, further comparative investigation of the 
transition process is needed.
Transition outcomes
Recently, several international Delphi studies 
were conducted aiming to identify outcomes 
Strengths and limitations of this study
 ► This is the first randomised controlled trial which 
aims to provide strong scientific evidence on the 
superiority of joint visits compared with standard 
transitional care in IBD.
 ► As the trial investigates the effect of joint transition 
visits on several individual and healthcare out-
comes, its results will help to better define the suc-
cess of the transition process and to determine the 
long- term influence of joint transition visits in IBD.
 ► Due to the nature of the study, double blinding is not 
applicable, as the gastroenterologists, the medical 
staff and the participants cannot be blinded.
 ► After 18 years of age, young adults tend to move 
to other cities for further education or employment, 
which involves the possibility of losing patients 
during the follow- up period.
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of transition. According to the data of non- disease- specific 
studies, patients not lost to follow- up, health- related quality 
of life (HRQoL), self- management and disease- specific 
knowledge are among the most important indicators of 
a successful transition.4 5 According to a multinational 
IBD- specific Delphi study, individual outcomes during 
transition were considered more important than disease- 
related items.6 As transitional care is a complex process, 
it is difficult to define and prioritise endpoints. Based on 
the most up- to date observations, individual, healthcare 
service and social outcomes should be taken equally into 
account as composite endpoints of a transition process in 
IBD.4–6
Transitional interventions
In a recent systematic review, several different struc-
tured transition interventions were identified aiming to 
improve transition- related outcomes.7 Joint visits were 
the most frequently applied interventions, which were 
held under different circumstances and were organised 
by multidisciplinary groups of different compositions all 
around the world.8–12 Non- randomised studies with low 
sample sizes and selection bias showed that joint visits 
may improve quality of life, medical adherence, patients’ 
satisfaction and able to optimise medical visit attendance 
rates.8 13–17 However, patient education programmes and 
the coordinating role of IBD nurses are also considered 
to be beneficial in structured transition interventions.18–23
Need for a trial
Since the quality of evidence proved to be very low for 
each transitional outcome, further trials are needed 
to determine the active ingredient and the long- term 
impact of these interventions.7 Joint visits were mainly 
held in the presence of a paediatric and an adult gastro-
enterologist (PGE and AGE, respectively), hence the 
real impact of the personal attendance of the AGE on 
the whole transition process is questionable. Moreover, 
the cost- effectiveness of transition programmes can be 
questioned. This randomised controlled trial (RCT) 
aims to establish evidence on whether joint transition 
visits for adolescents with IBD are superior to standard 
care.
Aim and hypothesis
This RCT aims to establish whether joint visits are superior 
to standard transitional care at improving the HRQoL for 
adolescents with IBD. We hypothesise that the personal 
interaction between the AGE and the adolescent during 
the transition period can significantly improve both indi-
vidual (HRQoL, medication adherence, self- efficacy, 
transition readiness, patient satisfaction) and healthcare 
outcomes (medical visit attendance, avoidance of unnec-
essary hospitalisations).
Figure 1 Flow chart of the study design.
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METHODS AND DESIGN
Trial organisation, committees and boards
TRANS- IBD is designed and coordinated by the Centre 
for Translational Medicine (http://www. tm- pte. org/; 
Medical School, University of Pécs), in which several clin-
ical trials have already been initiated (GOULASH, EMILY 
and ELEFANT24–26 on the field of gastroenterology aiming 
to improve the quality of healthcare). The study protocol 
was planned in accordance with the SPIRIT 2013 State-
ment (online supplemental material 1).27
Steering committee
The Steering committee (SC) will be led by PS (gastro-
enterologist). The members will be AE and DD (medical 
doctors, full- time employees on the project), PH (gastro-
enterologist), ÁV (gastroenterologist) and ATá (PGE). 
The SC will make decisions on all relevant questions 
concerning the participation and the dropouts during 
the study.
General study overview
This study is a prospective, multicentre RCT. The patient 
recruitment is performed in those gastroenterology 
centres of Hungary, where both paediatric and adult IBD 
clinics are available. Eligible adolescents, who have agreed 
to participate in our RCT, are randomised into two arms 
(figure 1). Patients in the intervention arm receive usual 
medical care plus a transition intervention for 1 year 
consisting of four joint sessions of experts including PGE 
and AGE. Transitional care with joint visits is not standard 
in the Hungarian medical care system. In the control arm, 
which corresponds to the standard of care in Hungary, 
participants follow their usual medical care without the 
presence of AGE at outpatient consultations. The inter-
vention period lasts between the ages of 17 and 18 (visits 
1–4; V1–V4); at the age of 18 transfer to adult gastroen-
terology is obligatory. After 1- year follow- up period at 
the adult healthcare system (visits 5–9; V5–V9), the trial 
ends at the age of 19 of the adolescents. During the study 
period, patients are not allowed to change study groups. 
In order to improve participants’ adherence to the study 
protocol, the next appointment of each visit is arranged 
in advance and rescheduled visits are also accepted.
Questionnaires are filled out at baseline, at the time of 
transfer to adult healthcare and at 1- year post- transfer. The 
monitoring of physical development, disease activity, health-
care utilisation and adverse events is continuous during the 
study. Patients in the intervention and control groups are 
treated by the same physician and under the same condi-
tions in each recruiting centre. Adolescents in both study 
groups are transferred to the same AGE. Modifications of 
therapy are easy to track because names of currently taken 
IBD- related drugs and side effects are recorded on the case 
report form, which is completed at each clinical visit during 
the study. To promote participant retention in the study and 
complete follow- up, patients planning to move to other city 
after the age of 18 are offered to be followed up by another 
AGE working in the destination city (who is also the partici-
pant of TRANS- IBD study).
Participating centres
Study participants are recruited from six tertiary paediatric 
care centres in Hungary (University of Pécs, Debrecen, 
Szeged, Central Hospital of Borsod- Abaúj- Zemplén County, 
Semmelweis University Budapest and Heim Pál Children’s 
Hospital). The adult gastroenterology sites are the corre-
sponding tertiary centres in Hungary, namely Pécs, Debrecen, 
Szeged, Miskolc and two additional centres from Budapest. 
The principal investigators at the various sites are members 
of the Hungarian Pediatric Gastroenterology Society and 
the Hungarian Society of Gastroenterology. The local inves-
tigators introduce the study to the adolescents and parents 
and provide a letter of information. As our study is an open- 
label trial, we aim to recruit further Hungarian and Central- 
Eastern European centres for participation. We welcome the 
joining of those IBD centres which can recruit eligible adoles-
cent participants and can provide the continuous participa-
tion of a PGE and an AGE at the joint visits. Centres with 
the intention of joining need to send a letter of intent to the 
corresponding author by email.
Inclusion and exclusion criteria
The inclusion criteria are: (1) established IBD diagnosis 
based on the modified ‘Porto Criteria’ at least 6 months prior 
to enrolment (date of the diagnostic endoscopy)28; (2) any 
form of IBD (including Crohn’s disease or ulcerative colitis) 
regardless of disease activity and treatment; (3) patient aged 
between 16.75 and 17 years at allocation; (4) at least one 
visit attendance at the PGE in the year prior to enrolment 
(aiming to minimise non- adherence with the intervention); 
(5) signed written informed consent from the legal guardian 
and informed assent from the patients.
The exclusion criteria are: (1) diagnosis of unclassified 
IBD; (2) pregnancy; (3) medically certified developmental or 
intellectual disabilities (when it is expected that the patient 
is unable to fill the questionnaires); (4) history of cancer or 
active cancer treatment; (5) body mass index ≥40, to elimi-
nate the impact of potential comorbidities on our primary 
outcome; (6) concomitant participation in another interven-
tional clinical trial; (7) conditions when follow- up cannot be 
fulfilled (eg, plan for studying or working abroad after the 
age of 18).
Patient and public involvement
During the trial planning stage, adolescents’ preferences 
were taken into account. To involve patients in the develop-
ment of study protocol, we invited five adolescents with IBD 
to revise two version of the study protocol. In the first version, 
the intervention period lasted for 2 years between the ages 
of 16 and 18 with joint transition visits in every sixth months. 
In the second version, the intervention period was planned 
for only 1 year just before the transfer to the adult health-
care with joint visits held in every third month. The invited 
patients assessed the burden of the intervention in case of 
both study versions and reported greater preferences for the 
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second version of the protocol. The results of the study will be 
disseminated to the participants through the AGEs involved 
in the study. Herewith, we would like to thank the adolescents 
who were actively involved in the development of our study 
protocol.
Recruitment
Eligible adolescents (aged 16.75–17 years) treated with IBD 
and their parents are informed about the possibility to partic-
ipate in the study. After the PGE has expounded the main 
points of the trial, adolescents and their legal guardians 
should confirm their intention to participate by signing the 
informed consents. The flow chart of the study is summarised 
in figure 1.
Baseline assessment
At the first transition visit, right before randomisation, self- 
reported background information questionnaire is obtained 
from patients, comprising sociodemographic variables such 
as age, gender, ethnicity, birth, level of education, number 
of siblings, living situation, family structure, parent’s highest 
level of education and smoking habits. Medical history (date 
of diagnosis, Paris classification at diagnosis,29 previous 
abdominal surgeries, medications and adverse events), 
comorbidities, body weight, height, concomitant medica-
tions, disease activity (assessed with adult and paediatric 
disease activity indices and stool calprotectin),30–33 standard 
laboratory parameters (haematology, biochemistry and 
inflammatory markers) and utilisation of healthcare services 
(in the previous 3 months) are also assessed. Additionally, the 
questionnaires measuring transition- related outcomes are 
also filled out by the participants (listed among the primary 
and secondary outcomes).
Randomisation and blinding
After obtaining the informed consents at visit 1 (V1), in 
each participating centre, patients are block- randomised 
with a random variable block sizes of two, four and six to the 
intervention group or the comparison group beside a 1:1 
allocation ratio. A randomisation list will be generated for 
each participating centre by the biostatistician group of the 
Centre for Translational Medicine with the application of 
a computer program. Sequentially numbered, sealed enve-
lopes will contain the assigned treatment group for the next 
participant.
Due to the nature of the study, the blinding of the 
participants and personnel (PGE, AGE, medical staff) is 
not possible, however, the blinding of the data managers 
and statisticians will be secured.
Balanced consultation
In the strict sense, our study involves two different interac-
tions: (1) the interaction between the PGE and the AGE and 
(2) the interaction between the AGE and the adolescent. 
The aim of this study is to assess the effect of the interaction 
between the AGE and the adolescent. Balanced consultations 
are carried out to eliminate the bias caused by the physician–
physician interaction, which are not currently part of the 
standard clinical care in Hungary. Balanced consultations 
are held in both study groups, before each visit during the 
intervention period, and provide an opportunity for the AGE 
to make recommendations on the patient’s medical history 
and the actual treatment options. The two gastroenterolo-
gists should also have a discussion regarding the information 
package that is provided for the participant in connection 
with the transition process (online supplementary material 
2). In summary, a balanced consultation is a clinical review 
between the two gastroenterologists without the presence of 
the adolescents involved.
Elimination of other confounding factors
Beside balanced consultation, we aim to minimise all the 
other potential confounding factors. Regarding treatment 
plan, the guidelines of the European Crohn’s and Colitis 
Organisation are followed in both groups.34–36 All patients 
access services that address their healthcare needs. If indi-
cated, dietitian, psychologist and surgeon are available for 
every participant.
Regardless of the study group, patient education 
comprises information about the transition- related topics 
controlled by the predefined ‘TRANS- IBD Information 
sheets 1–4’ (online supplementary material 2). In both 
study groups, the transfer from paediatric to adult care 
includes a scheduled appointment at the previously 
assigned AGE and a letter summarising the patient’s 
medical history.
Intervention (treatment) group
In our clinical trial, the structured transition intervention is 
the application of joint transition visits with the simultaneous 
participation of the PGE and the AGE. In order to maximise 
the effect of the intervention, the implementation of four 
joint visits during the 1- year intervention period was chosen. 
The four face- to- face sessions take place every third month 
between the ages 17 and 18 and are localised at the paedi-
atric outpatient clinic (=transition clinic). Each joint visit lasts 
at least for 20 min in length, although in case of complex 
medical history, there is no restriction with respect to the 
length of the visit. Joint transition visits 1, 2 and 3 (V1–V3) 
are led by the PGE but visit 4 (V4) is led by the AGE. During 
joint transition visits, transition and age- related topics are 
discussed (online supplementary material 2).
Control group (usual care)
Patients in the control group are given standard of care and 
visit their PGE every 3 months between their 17 and 18 years 
of age. As patients in the control group do not participate 
on joint visits, they have no contact with the AGE through 
the intervention period. During medical visits with the PGE, 
transition and age- related topics are discussed likewise in 
the intervention group (online supplementary material 2). 
Before each visit, balanced consultation is performed about 
the adolescent’s treatment plan to ensure equality.
Outcome measures
Careful selection of outcome measures for adolescents is 
important to ensure reliability, objectivity and feasibility. 
Outcome measures of our study were selected based on 
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three international consensus publications and two system-
atic reviews.4–7 37 In the development phase, final items 
were chosen with the stakeholder reference group through 
discussion. In table 1, an overview of all variables and 
instruments at each time point is provided. Primary and 
secondary outcomes are assessed at baseline, at the end of the 
intervention period and at the end of the follow- up period. 
The questionnaires used in our study are validated and most 
of them are disease specific. Forward–backward translation 
of the questionnaires was performed by two independent 
native Hungarian speakers with excellent knowledge of 
English. The IMPACT- III questionnaire is a valid and reliable 
Table 1 Schedule of enrolment, interventions and assessments







Visit 2–3–4* Visit 5 Visit 6–7–8* Visit 9
19 years±30 days
Enrolment
  Eligibility screen x   
  Informed consent x   
  Allocation x   
Interventions
  Intervention group PGE PGE+AGE PGE+AGE AGE AGE AGE
  Control group PGE PGE PGE AGE AGE AGE
Assessments
  Demographic data x x  x
  Medical history x   
  Physical examination† x x x x x
  Body height and weight  x x x x x
  Actual medications x x x x x
  Adverse events x x x x x
  Disease activity (PUCAI/PCDAI) x x x x x
  Disease activity (Mayo/CDAI/
perianal CDAI)
x x x x x
  Healthcare utilisation‡ x x x x x
  Serum sample§  x x x x x
  Stool sample¶  x  x  x
Questionnaires
  Self- efficacy (IBDSES- A) x x  x
  Transition readiness (TRAQ) x x  x
  Transition readiness (STARx- 
adolescent version)
x x  x
  Transition readiness (STARx- 
parent version)
x x  x
  HRQoL (IMPACT- III) x x x** x
  Patient satisfaction (CACHE) x x  x
  Medication adherence (MARS-5) x x  x
X = scheduled measurements.
*During the study, visits are held in every three months (±30 days).
†First visit: complete physical examination; further visits: symptom- oriented physical.
‡IBD- related healthcare utilisation (considering the last 3 months): 1. number of unscheduled visits at the caregiver gastroenterologist; 2. number 
of unplanned/unscheduled visits at the emergency department; 3. number of scheduled and urgent imaging; 4. number of scheduled and urgent 
endoscopies; 5. number and type of surgical interventions; 6. number of IBD- related hospital admissions; 7. length of hospitalisation.
§Determination of laboratory parameters (haematology, biochemistry, inflammatory markers).
¶Determination of stool calprotectin.
**HRQoL will be measured at visit 7.
AGE, medical visit with the adult gastroenterologist; CDAI, Crohn Disease Activity Index; HRQoL, health- related quality of life; IBD, inflammatory 
bowel disease; IBDSES- A, IBD Self- Efficacy Scale for adolescents and young adults; MARS-5, Medical Adherence Report scale; PCDAI, Paediatric 
Crohn’s Disease Activity Index; PGE, medical visit with the pediatric gastroenterologist; PGE + AGE, joint visit with the attendance of both pediatric 
and adult gastroenterologists; PUCAI, Paediatric Ulcerative Colitis Activity Index; STARx- adolescent, STARx Transition Readiness Questionnaire 
(Adolescent Version); STARx- parent, STARx Transition Readiness Questionnaire (Parent Version); TRAQ, Transition Readiness Assessment 
Questionnaire.
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questionnaire for assessing HRQoL of children with IBD, 
which has been already adapted in Hungary.38 The further 
questionnaires used for the assessment of the secondary 
outcomes will be adapted as part of the study.
Primary outcome
The primary outcome of our trial is the change in patient- 
reported HRQoL 1 year after transfer focusing on patients’ 
subjective evaluation about the impact of the disease on 
different health dimensions (including physical, emotional, 
social and cognitive functions).39 HRQoL is measured with 
a validated and IBD- specific QoL questionnaire.40 The 
IMPACT- III questionnaire, which has been already adapted 
in Hungary, consists of 35 items using a 5- point Likert self- 
completed response scale and asks about the severity and 
frequency of the following symptoms over the last 2 weeks: 
bowel symptoms, systemic symptoms, emotional functioning, 
social functioning, body image and treatments or inter-
ventions.38 The maximum of 175 points can be achieved. 
Higher scores indicate better HRQoL. Based on the recom-
mendation of a recently conducted multinational Delphi 
study on the transition care of adolescent with IBD, HRQoL 
should be assessed with IMPACT- III questionnaire at 1- year 
post- transfer.6
Secondary outcomes
The number of patients not lost to follow-up
Patients are not lost to the follow- up if they attend at 
least three out of the five planned AGE visits during 
the follow- up period after transfer to adult healthcare. 
Previously cancelled and then rescheduled AGE visits 
are acceptable. According to the study protocol, the first 
AGE visit should be held no later than 3–4 months after 
transfer.
Healthcare utilisation (measured in every 3 months)
We are administrating (1) the number of unplanned 
visits at the caregiver gastroenterologist; (2) the number 
of unplanned visits at the emergency department; (3) 
the overall number of scheduled and urgent imaging 
performed (including abdominal ultrasound, X- ray, MRI, 
CT scan, other); (4) the overall number of scheduled 
and urgent endoscopies performed (including gastro-
duodenoscopy, colonoscopy); (5) the number and type 
of surgical interventions; (6) the number of IBD- related 
hospital admissions and (7) the length of disease- related 
hospitalisation (given in days).
Disease activity
We will calculate both the paediatric and adult activity 
indexes at each visit (Paediatric Crohn’s Disease Activity 
Index; Paediatric Ulcerative Colitis Activity Index; Crohn’s 
Disease Activity Index, CDAI, Mayo score and perianal 
CDAI) and measure the inflammatory laboratory param-
eters at each visit (eg, C- reactive protein, erythrocyte 
sedimentation rate and white blood cell); and the level 
of stool calprotectin once a year.30–33 41 We will record the 
number of patients who needed the initiation of corti-
costeroid treatment and biological treatment and also 
the number of flare- ups. Flare- ups are defined as clinical 
symptoms suggesting disease activity, accompanied with 
biochemical (eg, stool calprotectin, CRP), endoscopic or 
imaging evidence of inflammation. Intensifying disease 
symptoms resulting in dose escalation or initiation of a 
new drug aiming to achieve remission is also considered 
as flare- ups.
Medication adherence
Medication adherence is measured with the Medical 
Adherence Report Scale (MARS-5), which has been 
already validated in several countries.42–44 MARS-5 is a 
shortened and modified version of the original MARS 
questionnaire, which consists of five statements with 
respect to the patient’s medical adherence in the last 
1 week.45 Patients can describe their behaviour on a 
5- point Likert response scale ranging from ‘always’ to 
‘never’ (1–5 points). The lowest total score that can be 
achieved is 5 (lowest adherence), while the highest is 
25 (maximal adherence). Higher scores indicate better 
medical adherence.
The longitudinal change of patient-reported HRQoL during the trial
HRQoL will be measured at baseline, at the beginning 
(V5), in the middle (V7) and at the end (V9) of the 
follow- up period.
Self-efficacy
Self- efficacy is measured with a valid, IBD- specific ques-
tionnaire named: IBD Self- Efficacy Scale for adolescents 
and young adults (IBDSES- A).46–48 Through the 13 
disease- specific items, IBDSES- A investigates the person’s 
confidence in their ability to manage demands and is 
predictive of health outcomes in chronic disease such as 
hospitalisation and health status. Answers can be given 
on a 5- point Likert response scale in case of every item. 
The maximum scores range from 21 to 57 (as reverse 
scoring is used in case of two items). Higher scores indi-
cate higher self- efficacy.
Transition readiness
Transition readiness is measured with the validated 
tools of Transition Readiness Questionnaire (STARx) 
and the Transition Readiness Assessment Questionnaire 
(TRAQ).49–52
STARx consists of three modules (with a total of 18 
items), aiming to investigate the sense of responsibility, 
and the independency of the patients.49 Each item can be 
answered using a 5- point Likert response scale and can 
be scored between 1 and 5 points. The maximum score 
is 90. Since we would like to compare how adolescents 
themselves and their parents judge participants’ transi-
tion readiness, STARx is filled out by the participating 
adolescents and by their legal guardian too.49 52
TRAQ consisting of 20 items and assesses the adoles-
cents’ willingness to be involved in or to be completely 
independent in managing disease- related tasks (eg, taking 
medications, making appointments, getting medications 
prescribed).50 A 5- point Likert response scale (with scores 
ranging from 1 to 5) is used for answering each question. 
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A total of 100 points can be acquired. In case of both tool, 
higher total scores indicate a higher level of transition 
readiness.
Although both questionnaires assess adolescents’ transi-
tion readiness, and some of their questions are almost the 
same, it should be noted that certain areas of transition 
readiness occur only in one of the two questionnaires. For 
example, only TRAQ asks questions about documenting 
health tasks, while STARx do not ask this topic.49 50 On the 
other hand, STARx examines disease- specific knowledge 
in more detail.49
Patient’s satisfaction
Patients’ satisfaction is assessed with a validated, IBD- 
specific tool called CACHE questionnaire, which consists 
of 31 questions with respect to the attitude of the medical 
team, the location, accessibility and facilities of the IBD 
centre.53 Questions can be answered with a 5- point Likert 
response scale. The final score can be given on a scale that 
ranges from 0 (minimum satisfaction) to 100 (maximum 
satisfaction). The final total score is calculated with stan-
dardisation, using the following formula to determine the 
points of each individual item: (real score − minimum 
score)/(maximum score − minimum score) ×100.
Data collection and management
The data collected will be handled and validated by an 
Independent Data Management Board (IDMB). In addi-
tion, IDMB will perform the independent assessment of 
the trial- related files and activities aiming to ensure the 
safety of the participants and guarantee the reliability of 
the collected data. In all cases, the IDMB will perform an 
audit of the centres wishing to join and will report to the 
SC.
The data collection is continuous during the intervention 
and follow- up period. The interventions, the measured vari-
ables and the applied instruments with their specified time 
points are listed for both study groups in table 1. First, data 
are collected on paper by filling out the case report forms 
(online supplementary material 3). The visit forms (including 
the patient’s actual symptoms, laboratory parameters, score 
of activity indices, ongoing therapy, the result of the phys-
ical examination and the imaging studies) are filled out by 
the study nurse. The study nurse is the regular nurse who is 
involved in the adolescent’s healthcare. The questionnaires 
are filled out also on paper by the participants and parents. 
Thereafter, the completed visit forms and questionnaires will 
be entered to a centralised electronic data storage system by 
administrators. Patients’ data are stored anonymously. Paper- 
based documentations containing personal data can only be 
accessed by those directly involved in the research.
Adverse events and safety
Due to the nature of the intervention, the occurrence of 
intervention- related serious adverse events is not expected. 
However, adverse events (eg, adverse drug experiences) will 
be collected from the time of signing the informed consent.
Drop-out
The collected data will be analysed separately for the 
intention- to- treat and also for the per- protocol study popu-
lations. The intention- to- treat analysis will include the data of 
all participants who are randomised in the study, even if they 
violate the protocol or have missing data. The per- protocol 
analysis will include the data of patients who complete the 
study according to the requirements of the study protocol. 
Patients automatically drop- out from the per- protocol anal-
ysis if: (1) at least one joint visit is missed; or (2) any of the 
data considering the primary endpoints cannot be obtained 
from the participant.
Sample size
Sample size calculation was based on the article of Cohen et al 
and was performed by the biostatistician team of the Institute 
of Translational Medicine.54 Based on the available data, we 
expect nine points difference between the mean IMPACT- III 
points of the intervention and control group at the end of the 
study. In order to detect this difference between the two study 
groups, 160 patients are needed to be recruited (80/group) 
using a 21% drop- out rate, 80% power and 95% significance 
level.
Statistical analyses
The baseline characteristics of the participants will be anal-
ysed using descriptive analysis. The data on baseline charac-
teristics and demographic will be described for the overall 
study population and for the intervention and control groups 
separately, to reveal any significant difference between the 
two study populations. In case of continuous variables, mean, 
median, SD and the quartiles of 25 and 75 will be used to 
display the results. In case of categorical variable, the results 
will be described by using absolute or relative frequencies. In 
case of normal distribution, independent T- test will be used 
to compare the results of the two study groups, otherwise 
Mann- Whitney test will be applied. The primary outcome 
HRQoL will be analysed with analysis of covariance, taking 
into account disease activity as an influencing factor. For 
the longitudinal analysis of HRQoL, a mixed model with 
a proper covariate matrix will be performed. As for the 
secondary outcomes, the relative risk will be calculated for 
dichotomous variables and the T- test will be performed for 
continuous variables.
Interim analyses and premature termination of the study
Since the recruitment period is expected to be shorter than 
the follow- up period, no interim analysis will be performed 
during the study.
Trial duration
The starting date of the trial is 1 September 2020 and the 
expected date of finishing the recruitment is 1 September 
2024.
Dissemination and publication policy
Findings will be disseminated at research conferences and in 
medical journals. Centres can add one or more authors to 
the authorship list if they: (1) make a substantial contribution 
8 Erős A, et al. BMJ Open 2020;10:e038410. doi:10.1136/bmjopen-2020-038410
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to the acquisition of the data (recruiting at least 25 partici-
pants) and; (2) ensure that questions related to the conduc-
tion of the investigation are appropriately investigated and 
resolved and; (3) take part in the critical review of the draft 
version of the work and; (4) give their final approval of the 
version to be published.
Ethics
The protocol has been approved by the Scientific and 
Research Ethics Committee of the Medical Research 
Council (reference number: 50457-2/2019/EKU). Site- 
specific approval has been granted by local RECs at all 
trial sites. The study will be performed in accordance with 
the Declaration of Helsinki and the principles of Interna-
tional Council for Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human 
Use- Good Clinical Practice (ICH-GCP) guidelines.55 56
DISCUSSION
Here we present the protocol of a prospective, randomised, 
multicentre, controlled trial (TRANS- IBD) aiming to inves-
tigate the influence of joint transition visits in IBD. Recent 
guidelines recommend the performance of joint visits during 
the transition period, but the strong evidence proving their 
superiority compared with usual care is still missing.2 3 Our 
main hypothesis is that the introduction of joint visits with the 
personal attendance of the AGE will significantly improve the 
individual HRQoL of the adolescents compared with usual 
care. Additionally, this structured transition intervention 
can also help to improve transition- related outcomes, such 
as patient satisfaction, and transition readiness, leading to 
increased quality of healthcare. We assume that this trial is 
suitable for detecting the multiple beneficial effects of joint 
visits. Considering ethical issues, participation means a very 
low risk for patients both in the intervention and control 
groups.
CONCLUSION
This RCT will provide a high quality of evidence 
concerning the value of joint visits compared with the 
usual transition care in IBD. Our results will help to 
define to which extent the joint visits can improve indi-
vidual, IBD- specific and transition- related outcomes.
Author affiliations
1Institute for Translational Medicine, Medical School, University of Pécs, Pécs, 
Hungary
2Heim Pál Children’s Hospital, Budapest, Hungary, Budapest, Hungary
3Szentágothai Research Centre, Medical School, University of Pécs, Pécs, Hungary
4First Department of Pediatrics, University of Debrecen, Hungary, Debrecen, 
Hungary
5Department of Pediatrics, Medical School, University of Pécs, Pécs, Hungary
6First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary, 
Pécs, Hungary
7Momentum Gastroenterology Multidisciplinary Research Group, Hungarian 
Academy of Sciences, University of Szeged, Szeged, Hungary
Contributors All authors read through and made suggestions on the text of the 
manuscript. The final manuscript was approved by all the authors. AE, GV, PH, ÁV 
and PS conceptualised the idea of the study. AE, GV, ÁV, PS determined the design 
of the trial. ZN and DD arranged project administration. The original draft of the 
manuscript was written by AE, DD and PS. The original draft was reviewed and 
edited by GV, AT, ATé, PH, ZN, ÁV and NG. The statistical work was performed by NG.
Funding Centre costs (IT, biostatistics, trial organisation, etc) are covered by the 
project titled 'GINOP-2.3.2-15-2016-00048 – STAY ALIVE' which is cofinanced by 
the European Union (European Regional Development Fund) within the framework 
of Programme Széchenyi 2020, by the Human Resources Development Operational 
Programme Grant, Grant Number: EFOP‐3.6.2‐16‐2017‐0006 – LIVE LONGER, 
which is cofinanced by the European Union (European Regional Development 
Fund) within the framework of Programme Széchenyi 2020, and by the Grant of 
the Hungarian Science Foundation (Grant Number: FK 132834). Since no additional 
treatment is necessary for the study, the general healthcare costs are covered by 
the National Healthcare System. This study was designed with help of the Centre 
for Translational Medicine at the University of Pécs. This centre is committed to 
improve patients’ life with research activities (http://www. tm- pte. org/).
Competing interests None declared. Principal investigators of each study sites 
decline any financial and other competing interests.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting or dissemination plans of this research. Refer to the 
Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Patrícia Sarlós http:// orcid. org/ 0000- 0002- 5086- 9455
REFERENCES
 1 Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity 
and chronic health conditions among children and youth. JAMA 
2010;303:623–30.
 2 Brooks AJ, Smith PJ, Cohen R, et al. Uk guideline on transition of 
adolescent and young persons with chronic digestive diseases from 
paediatric to adult care. Gut 2017;66:988–1000.
 3 van Rheenen PF, Aloi M, Biron IA, et al. European Crohn's and colitis 
organisation topical review on transitional care in inflammatory bowel 
disease. J Crohns Colitis 2017;11:1032–8.
 4 Suris J- C, Akre C. Key elements for, and indicators of, a successful 
transition: an international Delphi study. J Adolesc Health 
2015;56:612–8.
 5 Fair C, Cuttance J, Sharma N, et al. International and interdisciplinary 
identification of health care transition outcomes. JAMA Pediatr 
2016;170:205–11.
 6 van den Brink G, van Gaalen MAC, de Ridder L, et al. Health care 
transition outcomes in inflammatory bowel disease: a multinational 
Delphi study. J Crohns Colitis 2019;13:1163–72.
 7 Erős A, Soós A, Hegyi P, et al. Spotlight on transition in patients with 
inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 
2020;26:331–46.
 8 Cole R, Ashok D, Razack A, et al. Evaluation of outcomes in 
adolescent inflammatory bowel disease patients following transfer 
from pediatric to adult health care services: case for transition. J 
Adolesc Health 2015;57:212–7.
 9 Fu N, Jacobson K, Round A, et al. Transition clinic attendance is 
associated with improved beliefs and attitudes toward medicine in 
patients with inflammatory bowel disease. World J Gastroenterol 
2017;23:5405–11.
 10 McCartney S, Lindsay JO, Russell R, et al. Structured transition 
enhances clinical outcome without an increase in healthcare cost in 
adolescent patients with IBD: the UK transit study. Gastroenterology 
2017;152:S369–S69.
 11 Moulton DE, Rosen MJ, Beaulieu DB, et al. Su2015 prospective 
randomized trial of a progressive pediatric to adult transition of 
care program in adolescents with inflammatory bowel disease. 
Gastroenterology 2013;144:S-532–S32.
 12 Otto C, Tárnok A, Erős A, et al. Planned transition of adolescent 
patients with inflammatory bowel disease results in higher remission 
rates. J Pediatr Nurs 2019;45:62–6.
9Erős A, et al. BMJ Open 2020;10:e038410. doi:10.1136/bmjopen-2020-038410
Open access
 13 Romeo E, Ricca O, Angelino G, et al. Transition clinic in inflammatory 
bowel disease: a two centre model. Journal of Pediatric 
Gastroenterology and Nutrition 2016;62:338.
 14 Yerushalmy- Feler A, Ron Y, Barnea E, et al. Adolescent transition 
clinic in inflammatory bowel disease: quantitative assessment of self- 
efficacy skills. Eur J Gastroenterol Hepatol 2017;29:831–7.
 15 Alfano G, Nuzio SG, Poeta M, et al. Health care transition of patients 
with pediatric onset inflammatory bowel disease: a pilot survey. 
Journal of Pediatric Gastroenterology and Nutrition 2016;62:347.
 16 Blazquez ML, Hernani MT, Calatayud GA, et al. Transition care 
program of adolescents with inflammatory bowel disease: 
perceptions from a survey for patients.. Inflamm Bowel Dis 2018.
 17 Williams E, Coates M, Tinsley A, et al. Formalized IBD transition clinic 
leads to high retention and low no show rates of young adults in a 
single tertiary center. Am J Gastroenterol 2017;112:S388–9.
 18 Schmidt S, Herrmann- Garitz C, Bomba F, et al. A multicenter 
prospective quasi- experimental study on the impact of a transition- 
oriented generic patient education program on health service 
participation and quality of life in adolescents and young adults. 
Patient Educ Couns 2016;99:421–8.
 19 Schmidt S, Markwart H, Bomba F, et al. Differential effect of a 
patient- education transition intervention in adolescents with IBD vs. 
diabetes. Eur J Pediatr 2018;177:497–505.
 20 Boamah LM, Bohren JR, Pentiuk S, et al. Development and testing 
of a CD- ROM program for improving adolescent knowledge 
of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 
2010;50:1–5.
 21 KKH V, Zhang Y, Denson LA, et al. Evaluation of a novel educational 
tool in adolescents with inflammatory bowel disease: the neat study. 
Journal of Pediatric Gastroenterology and Nutrition 2016;63:S66.
 22 Zhu X- Q, Li R- X, Chen F. Impact of transitional care on self- 
management ability and quality of life in patients with inflammatory 
bowel disease. World Chinese Journal of Digestology 2016;24:3723.
 23 Bennett AL, Moore D, Bampton PA, et al. Outcomes and 
patients' perspectives of transition from paediatric to adult 
care in inflammatory bowel disease. World J Gastroenterol 
2016;22:2611–20.
 24 Márta K, Szabó AN, Pécsi D, et al. High versus low energy 
administration in the early phase of acute pancreatitis (GOULASH 
trial): protocol of a multicentre randomised double- blind clinical trial. 
BMJ Open 2017;7:e015874.
 25 Kucserik LP, Márta K, Vincze Áron, et al. Endoscopic sphincterotoMy 
for delayIng choLecystectomy in mild acute biliarY pancreatitis 
(EMILY study): protocol of a multicentre randomised clinical trial. 
BMJ Open 2019;9:e025551.
 26 Zádori N, Gede N, Antal J, et al. Early elimination of fatty acids iN 
hypertriglyceridemia- induced acuTe pancreatitis (ELEFANT trial): 
protocol of an open- label, multicenter, adaptive randomized clinical 
trial. Pancreatology 2020;20:369–76.
 27 Chan A- W, Tetzlaff JM, Altman DG, et al. Spirit 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 28 Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria 
for the diagnosis of inflammatory bowel disease in children and 
adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.
 29 Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the 
Montreal classification for inflammatory bowel disease: the Paris 
classification. Inflamm Bowel Dis 2011;17:1314–21.
 30 Hyams JS, Ferry GD, Mandel FS, et al. Development and validation 
of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol 
Nutr 1991;12:439–47.
 31 Turner D, Otley AR, Mack D, et al. Development, validation, and 
evaluation of a pediatric ulcerative colitis activity index: a prospective 
multicenter study. Gastroenterology 2007;133:423–32.
 32 Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's 
disease activity index. National cooperative Crohn's disease study. 
Gastroenterology 1976;70:439–44.
 33 Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive 
components of the Mayo score to assess clinical response in 
ulcerative colitis. Inflamm Bowel Dis 2008;14:1660–6.
 34 Turner D, Ruemmele FM, Orlanski- Meyer E, et al. Management of 
paediatric ulcerative colitis, part 1: ambulatory Care- An evidence- 
based guideline from European Crohn's and colitis organization and 
European Society of paediatric gastroenterology, hepatology and 
nutrition. J Pediatr Gastroenterol Nutr 2018;67:257–91.
 35 Turner D, Ruemmele FM, Orlanski- Meyer E, et al. Management 
of paediatric ulcerative colitis, part 2: acute severe Colitis- An 
evidence- based consensus guideline from the European Crohn's 
and colitis organization and the European Society of paediatric 
gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol 
Nutr 2018;67:292–310.
 36 Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of 
ECCO/ESPGHAN on the medical management of pediatric Crohn's 
disease. J Crohns Colitis 2014;8:1179–207.
 37 Clarke T, Lusher J. Transitioning patients with inflammatory bowel 
disease (IBD) from adolescent to adult services: a systematic review. 
Frontline Gastroenterol 2016;7:264–70.
 38 Szabó D, Kökönyei G, Arató A, et al. Autoregressive cross- lagged 
models of IMPACT- III and pediatric Crohn's disease activity indexes 
during one year infliximab therapy in pediatric patients with Crohn's 
disease. J Crohns Colitis 2014;8:747–55.
 39 Landolt MA, Valsangiacomo Buechel ER, Latal B. Health- Related 
quality of life in children and adolescents after open- heart surgery. J 
Pediatr 2008;152:349–55.
 40 Otley A, Smith C, Nicholas D, et al. The impact questionnaire: a valid 
measure of health- related quality of life in pediatric inflammatory 
bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557–63.
 41 Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a 
new scoring system to evaluate and predict outcome of surgical 
intervention. Arch Surg 2002;137:774–7.
 42 SOLE Study Group. Translation and initial validation of the 
medication adherence report scale (MARs) in Italian patients with 
Crohn's disease. Dig Liver Dis 2019;51:640–7.
 43 Mahler C, Hermann K, Horne R, et al. Assessing reported adherence 
to pharmacological treatment recommendations. translation and 
evaluation of the medication adherence report scale (MARs) in 
Germany. J Eval Clin Pract 2010;16:574–9.
 44 Chan AHY, Horne R, Hankins M, et al. The medication adherence 
report scale: a measurement tool for eliciting patients' reports of 
nonadherence. Br J Clin Pharmacol2019.
 45 Horne R, Weinman J. Patients' beliefs about prescribed medicines 
and their role in adherence to treatment in chronic physical illness. J 
Psychosom Res 1999;47:555–67.
 46 Izaguirre MR, Keefer L. Development of a self- efficacy scale for 
adolescents and young adults with inflammatory bowel disease. J 
Pediatr Gastroenterol Nutr 2014;59:29–32.
 47 Carlsen K, Haddad N, Gordon J, et al. Self- Efficacy and 
resilience are useful predictors of transition readiness scores in 
adolescents with inflammatory bowel diseases. Inflamm Bowel Dis 
2017;23:341–6.
 48 Izaguirre MR, Taft T, Keefer L. Validation of a self- efficacy scale for 
adolescents and young adults with inflammatory bowel disease. J 
Pediatr Gastroenterol Nutr 2017;65:546–50.
 49 Ferris M, Cohen S, Haberman C, et al. Self- Management and 
transition readiness assessment: development, reliability, and 
factor structure of the STARx questionnaire. J Pediatr Nurs 
2015;30:691–9.
 50 Anelli CG, Len CA, Terreri MTRA, et al. Translation and validation of 
the transition readiness assessment questionnaire (TRAQ). J Pediatr 
2019;95:180–7.
 51 Sawicki GS, Lukens- Bull K, Yin X, et al. Measuring the transition 
readiness of youth with special healthcare needs: validation of the 
TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr 
Psychol 2011;36:160–71.
 52 Nazareth M, Hart L, Ferris M, et al. A parental report of youth 
transition readiness: the parent STARx questionnaire (STARx- P) 
and re- evaluation of the STARx child report. J Pediatr Nurs 
2018;38:122–6.
 53 Casellas F, Ginard D, Vera I, et al. Development and testing of a 
new instrument to measure patient satisfaction with health care 
in inflammatory bowel disease: the Cache questionnaire. Inflamm 
Bowel Dis 2013;19:559–68.
 54 Cohen SA, Aloi M, Arumugam R, et al. Enteric- Coated budesonide 
for the induction and maintenance of remission of Crohn's disease in 
children. Curr Med Res Opin 2017;33:1261–8.
 55 World Medical Association. World Medical association Declaration 
of Helsinki: ethical principles for medical research involving human 
subjects. JAMA 2013;310:2191–4.
 56 Dixon JR. The International Conference on harmonization good 
clinical practice guideline. Quality Assurance 1999;6:65–74.
